Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2013 Earnings Presentation

90 slides from Aspen Pharmacare's earnings presentation, February 2013

  1. Slide 1: Interim Results 31 December 2012

    Interim Results 31 December 2012

  2. Slide 2: From two rooms to R70bn

    From two rooms to R70bn O' aie TEPHEN SAAD pw BUSINESS | Leer $ SZ E JOHANNESBURG STOCK EXCHANGE I / ANN SRI Index meno Excellence in integrated Reporting Awards 2012 aod Aspen Pharmacare m Aspen Pharmacare Holdings ers’ From Emerging BCG Names 400 ‘Global Challeng al Industries Markets That Are Res

  3. Slide 3: Leadership: Business Leader of the Year

    Leadership Stephen Saad awarded Sunday Times “Business Leader of the Year” 3

  4. Slide 4: Return on Investment: Top 100 Companies

    Return on Investment Ranked 10th in the Sunday Times’ Business Times 2012 Top 100 Companies 4

  5. Slide 5: Generic Supplier of the Year to Sigma

    Customer Service Generic Supplier of the Year to Sigma Tim Burrows (Aspen National Sales Manager, Generics), Alan O’Hara (Sigma General Manager Supply Chain and Transformation), Wayne Marinoff (Aspen Head of Generics), Kevin Tymensen (Aspen Marketing Manager, Generics) and Jeff Sells (Sigma CFO) 5

  6. Slide 6: Supplier of the Year to Dis-Chem

    Customer Service Supplier of the Year to Dis-Chem 6

  7. Slide 7: President's Manufacturer of the Year in Tanzania

    Manufacturing Achievement President’s Manufacturer of the Year in Tanzania Issa Hango (Shelys Pharmaceuticals, Production Manager) & HE Jakaya Mrisho Kikwete (President of Tanzania) 7

  8. Slide 8: JSE SRI Index inclusion

    Socially Responsible Qualified for inclusion on the JSE’s SRI Index for the third consecutive year 8

  9. Slide 9: Golden Arrow Award by PMR

    Socially Responsible Golden Arrow Award by PMR Jackie Tau (Aspen, Group CSI Manager) 9

  10. Slide 10: Global Influence: BCG 100 Global Challengers

    Global Influence 1 of 5 South African Companies named in Boston Consulting Group’s 100 Global Challengers 10

  11. Slide 11: Global Investment: Ireland FDI honoree

    Global Investment Ireland Foreign Direct Investment (FDI) honoree 11

  12. Slide 12: Rated Excellent by Ernst & Young

    Excellence in Integrated Reporting Rated “Excellent” by Ernst & Young 12

  13. Slide 13: Excellence in Integrated Reporting

    Excellence in Integrated Reporting Ranked 4th overall by Nkonki overall highest in healthcare Prof. Steven Firer (Nkonki, Partner), Riaan Verster (Aspen, Company Secretary), Sindi Zilwa (Nkonki, CEO and Aspen Board Director) 13

  14. Slide 14: Highlights

    Highlights Revenue +20% to R9.0 billion • From continuing operations Operating profit +24% to R2.5 billion • From continuing operations Normalised diluted headline EPS +23% to 379 cents • From continuing operations Cash generated from operating activities +9% to R1.3 billion 14

  15. Slide 15: Abridged Statement of Comprehensive Income

    Abridged Statement of Comprehensive Income CONTINUING OPERATIONS 6 months ended 6 months ended 31 December 2012 31 December 2011 % R'million R'million change Revenue 8 997 7 505 +20% Cost of Sales (4 630) (3 929) Gross profit 4 367 3 576 +22% Operating expenses (1 803) (1 571) Other operating income

  16. Slide 16: Comparative reconciliation of earnings per share

    Comparative reconciliation of earnings per share ` 6 months ended 6 months ended % 31 December 2012 31 December 2011 change Cents Cents Basic earnings per share (EPS) 369.3 343.6 +7% Discontinued operations - (36.2) Basic EPS from continuing operations 369.3 307.4 +20% Impairments 1.6 9.0 Other 0.2

  17. Slide 17: Segmental contribution for six months ended December

    Segmental contribution for six months ended December Gross Revenue 2011 Gross Revenue 2012 International International South Africa South Africa 18% 18% 36% 37% Asia Pacific Asia Pacific Sub- 35% Sub-Saharan 36% Saharan Africa Africa 10% 10% Normalised EBITA 2011 Normalised EBITA 2012 International

  18. Slide 18: Gross revenue from continuing operations

    Gross revenue from continuing operations 4 000 +20% 3 500 +24% 3 000 R'million 2 500 2 000 1 500 +22% +2% 1 000 +38% +17% 500 - SA Pharma SA Consumer Asia Pacific Sub-Saharan Latin America Rest of the World Africa 2011 2012 According to customer geography 18

  19. Slide 19: Group operating margin

    Group operating margin 12 000 28.6% 30.0% 28.1% 10 000 9 695 26.8% 26.9% 27.5% 8 046 27.2% 8 000 25.0% Margin % R'million 6 144 22.5% 6 000 20.0% 4 570 4 142 4 000 17.5% 15.0% 2 000 12.5% - 10.0% H1 2009 H1 2010 H1 2011 H1 2012 H1 2013 Gross revenue Group EBITA margin - H1 EBITA – Operating profit b

  20. Slide 20: South African business review

    6 months ended December South African business review H1 performance 2012 2011 %  Solid growth in core pharmaceutical R'million R'million change business Revenue 3 566 2 908 +23%  Growing public sector ARV uptake EBITA 960 841 +14%  Greater weighting in public sector business EBITA margin 26.9% 2

  21. Slide 21: Asia Pacific business review

    6 months ended December Asia Pacific business review H1 performance 2012 2011 % R'million R'million change  Growth despite regulator price cuts  Acquisitions add to growth Revenue 3 383 2 859 +18%  Savings in COGS widens margin EBITA 949 736 +29%  On-going consolidation of manufacturing sites EB

  22. Slide 22: International business review

    6 months ended December International business review H1 performance 2012 2011 % R'million R'million change  Strong revenue growth from Latam  Rest of World revenue flat Revenue 1 756 1 443 +22%  Product acquisitions bolster growth EBITA 604 455 +33%  Improved margins by global brands EBITA marg

  23. Slide 23: Sub Saharan Africa business review

    6 months ended December Sub Saharan Africa business review H1 performance 2012 2011 % R'million R'million change  Further representation added to revenue Revenue 990 835 +19%  Political instability in Kenya and Nigeria EBITA 122 136 -10% constrained performance  Margin pressure from increased COG

  24. Slide 24: Abridged statement of financial position

    Abridged statement of financial position As at As at 31 December 2012 30 June 2012 ASSETS R'million R'million Non-current assets 25 442 21 287 Fixed assets 4 022 3 807 Intangible assets 15 566 11 870 Goodwill 5 592 5 344 Other non-current assets 262 266 Current assets 7 965 7 118 Cash 3 755 3 314 To

  25. Slide 25: Operating cash flows

    Operating cash flows 6 months ended 6 months ended % 31 December 2012 31 December 2011 change R'million R'million Cash operating profit 2 856 2 308 +24% Changes in working capital (867) (497) Cash generated from operations 1 989 1 811 +10% Net finance costs paid (230) (302) Tax paid (443) (298) Cash

  26. Slide 26: Investment in property, plant and equipment

    Investment in property, plant and equipment 1 000 900 800 700 R'million 600 598 500 400 300 630 636 651 470 200 302 100 - 2009 2010 2011 2012 2013 Incurred capital expenditure Incurred capital Forecast expenditure capex for remainder of the year Continuing capex spend 26

  27. Slide 27: Capital composition and debt pools

    Capital composition and debt pools Capital composition Net debt of R10.4 billion 100% as at 31 December 2012 90% 24% 34% 29% 80% 35% 52% International 70% 35.4% South Africa & 60% SSA 41.2% 50% 40% 76% 66% 71% 30% 65% 48% 20% 10% Asia Pacific 0% 23.4% FY 2009 FY 2010 FY 2011 FY 2012 H1 2013 Equity D

  28. Slide 28: Distribution of fund managers

    Distribution of fund managers As at December 2012 Europe 16% Asia Southern Pacific Africa 3% 53% Middle East 1% North America 27% As at June 2012 As at December 2011 Europe Europe 19% 21% Southern Asia Southern Africa Pacific Africa Asia 57% 3% 52% Pacific Middle 1% East Middle 1% East 1% North Nort

  29. Slide 29: Group Sales 6 months to December

    Group Group Sales 6 months to December SALES 2013 2012 Growth Rm Rm South Africa 3 566 2 908 23% Asia Pacific 3 383 2 859 18% Sub-Saharan Africa 990 835 19% International 1 756 1 443 22% Gross Sales 9 695 8 046 21% Less IFRS Adjustments (698) (541) 29% Total 8 997 7 505 20% 29

  30. Slide 30: South African Market: Private Market

    South Africa South African Market  Typical Emerging market ◦ Volume increases Private Market  Pricing determined by mechanism utilising exchange rates and CPI  Leads and lags effect margin ◦ 5.8% SEP increase will be implemented during March  Value of Pharma market dominated by branded/patented

  31. Slide 31: South African Market: Public and Consumer Market

    South Africa South African Market Public Market  Tender driven  Typically 2 year duration  ARV tender dwarfs all other tenders ◦ Margin challenged ◦ Anticipate major shift to 3-in-1s ◦ Requires specialist manufacturing technology  Aspen has about 1-in-4 share of every solid dispensed Consumer Ma

  32. Slide 32: South African Market: Legislative Environment

    South Africa South African Market Legislative Environment  International Benchmarking ◦ Progress being made  Logistics fee ◦ Complex  Proud participant of the PHEF ◦ PPP – healthcare sector ◦ Voluntary contribution − Boost skills in public sector − More doctors/ trained administrators − Skills im

  33. Slide 33: South Africa Pharmaceutical Market

    South Africa Pharmaceutical Market Total Private market as at Dec 2012 R27.17bn (Dec 2011: R25.34bn) • Market Growth 7% Other R0.75bn • Generic Branded (R0.866bn) Generics R6.62bn (R5.77bn) Ethical /Branded R12.31bn (R12.16bn) OTC R7.47bn (R6.55bn) 33

  34. Slide 34: Aspen South Africa

    South Africa Aspen South Africa Actual Performance SALES H1 2013 H1 2012 Growth Rm Rm Pharma 3 008 2 431 24% Consumer 558 478 17% 3 566 2 908 23% IMS Performance YTD Growth MAT Growth Pharma Division 6.65% 3.91% Ethicals - 0.62% - 4.81% Generics 13.65% 11.78% Vaccines 0.90% - 0.09% Source: IMS TPM D

  35. Slide 35: Performance of Aspen Pharmaceutical Business

    South Africa Performance of Aspen Pharmaceutical Business SALES H1 2013 H1 2012 Growth Pharma 3 008 2 431 24% Less tender ARVs and Intercompany (591) (270) 119% Adjusted Pharma base 2 417 2 161 12%  Return to double digit growth as predicted ◦ Drivers both new launches and organic growth  Anticipa

  36. Slide 36: Private Market Generics – MAT Value Share

    South Africa Private Market Generics – MAT Value Share Dec 2012 MAT Value Share of the Generics Market R6.62 bn (R5.7 bn 2011) .66% .64% .63% 5.23% .97% .84% 1.31% 1.13% ASPEN 1.80% 2.18% CIPLA MEDPRO 30.32% 2.57% ADCOCK INGRAM 2.65% NOVARTIS LUPIN LABORATORIES 2.74% SANOFI DAIICHI SANKYO SERVIER 3.

  37. Slide 37: Aspen has 5 of the top 6 Generic Brands

    South Africa Aspen has 5 of the top 6 Generic Brands Top 20 Generic Brands Aspen Product Source: IMS Trust in Aspen 37

  38. Slide 38: Performance of Tribuss

    South Africa Performance of Tribuss – South Africa’s Largest Generic Brand Mat Value Trend December Month Market Share by Value Now Market leader by both volume and value 38

  39. Slide 39: Public Sector - The ARV Effect

    South Africa Public Sector - The ARV Effect  H1 Aspen ARV sales were about R100m per month ◦ Prior year about R40m  Momentum will continue into H2 ◦ Still supplying prior tender buy in awards ◦ Expect to supply 3 in 1s for new tender  Projections for 2014 difficult at this stage ◦ Aspen tender aw

  40. Slide 40: Consumer Division Performance

    South Africa Consumer Division Performance SALES H1 2013 H1 2012 Growth Rm Rm Consumer Division 558 478 17%  Consumer growth excluding acquired OTCs is 14%  SA business growth driven primarily by Infacare ◦ Continues to enjoy strong organic growth  Future growth from innovations and range extensi

  41. Slide 41: South Africa Prospects

    South Africa Prospects  Growth to be maintained into H2  Private market has SEP increase and volume growth ◦ Pricing neutralised by forex increase ◦ Aspen expects organic volume growth to increase ◦ Aspen generic business - the primary growth driver  Public Sector ◦ Major tenders locked in  ARV

  42. Slide 42: Prospects – Volume Overview

    South Africa Prospects – Volume Overview  What management review and what gives us confidence  Organic sales growth is driven by Price and Volume  Price is managed by the regulator ◦ Leads and lags but input costs are broadly covered  Volume growth is a function of ◦ New product launches ◦ Organ

  43. Slide 43: South Africa's best pipeline

    South Africa Prospects - New Launch Income Value Generated during Dec 2012 MAT Period (New Launches < 24 Months) ASPEN ADCOCK SANOFI PFIZER NOVARTIS CIPLA ASTRAZENECA JOHNSON & MERCK & CO ROCHE INGRAM MEDPRO JOHNSON South Africa’s best pipeline 43

  44. Slide 44: New Launch Income - Aspen Trazadone

    South Africa Prospects – New Launch Income - Aspen Trazadone Significant market share captured in relatively short period in niche segment 44

  45. Slide 45: New Launch Income – Aspen Meropenem

    South Africa Prospects – New Launch Income – Aspen Meropenem Trust in new launches drive Aspen’s injectable value share Performance in specialist sector of private hospital market - a multinational dominated therapeutic class 45

  46. Slide 46: New Launch Income – Antibiotic Injectables

    South Africa Prospects – New Launch Income – Antibiotic Injectables Demonstration of trust in Aspen products by private hospital specialists. Historically dominated by multinationals. 46

  47. Slide 47: Organic Growth: top 10 products 2003

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2003 Product 10 Product 9 Product 8 Revenue Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 *excludes ARVs, Seretide and Foxair 9 year CAGR of 13.1% 4

  48. Slide 48: Organic Growth: top 10 products 2004

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2004 Product 10 Product 9 Revenue Product 8 Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2004 2005 2006 2007 2008 2009 2010 2011 2012 *excludes ARVs, Seretide and Foxair 8 year CAGR of 10.5% 48

  49. Slide 49: Organic Growth: top 10 products 2005

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2005 Product 10 Product 9 Revenue Product 8 Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2005 2006 2007 2008 2009 2010 2011 2012 *excludes ARVs, Seretide and Foxair 7 year CAGR of 15.1% 49

  50. Slide 50: Organic Growth: top 10 products 2006

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2006 Product 10 Product 9 Revenue Product 8 Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2006 2007 2008 2009 2010 2011 2012 *excludes ARVs, Seretide and Foxair 6 year CAGR of 13.6% 50

  51. Slide 51: Organic Growth: top 10 products 2007

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2007 Product 10 Product 9 Revenue Product 8 Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2007 2008 2009 2010 2011 2012 *excludes ARVs, Seretide and Foxair 5 year CAGR of 13.7% 51

  52. Slide 52: Organic Growth: top 10 products 2008

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2008 Product 10 Product 9 Revenue Product 8 Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2008 2009 2010 2011 2012 *excludes ARVs, Seretide and Foxair 4 year CAGR of 13.4% 52

  53. Slide 53: Organic Growth: top 10 products 2009

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2009 Product 10 Product 9 Revenue Product 8 Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2009 2010 2011 2012 *excludes ARVs, Seretide and Foxair 3 year CAGR of 11% 53

  54. Slide 54: Organic Growth: top 10 products 2010

    South Africa Prospects - Organic Growth* Revenue growth of Top 10 products in 2010 Product 10 Product 9 Revenue Product 8 Product 7 Product 6 Product 5 Product 4 Product 3 Product 2 Product 1 2010 2011 2012 *excludes ARVs, Seretide and Foxair 2 year CAGR of 13.5% 54

  55. Slide 55: South Africa Operations

    South Africa Operations  SA Operations continues to provide sustainable advantages ◦ The only company in SA currently manufacturing 3 in 1 ARVs ◦ Conversion increases are below inflationary increases − Volumes and double digit productivity improvements  Quality Underwrite ◦ SVPs inspected and appr

  56. Slide 56: High Potency Suite

    South Africa High Potency Suite  Niche technology  Site preparation has commenced  Expected construction completion – Sept 2014  Commissioning of equipment/utilities completed – Feb 2015  This facility fully funded by savings on products moved from other sites ◦ Savings of over 80% in conversio

  57. Slide 57: Aspen Asia Pacific

    Asia Pacific Aspen Asia Pacific 2011 2012 5% 7% Australia/NZ Australia/NZ Asia Asia 95% 93% Asia now at 7% of sales (by customer geography) R2 737m R156m 2012 2012 2011 2011 R3 217m R255m Australia/NZ - 18% growth Asia - 64% growth Our target is for Asia to have increasing share of this pie 57

  58. Slide 58: Aspen Australia

    Asia Pacific Aspen Australia DEC-2012 DEC-2011 TOTAL TOTAL Growth Rm Rm Australia 3 131 2 663 18% NZ 86 74 16% Aspen Australia total 3 217 2 737 18%  Aspen's portfolio consists of branded, generic and OTC products ◦ one stop shop  Aspen sells about 700 products  Aspen has more prescriptions writt

  59. Slide 59: Australia Market – December 2012

    Asia Pacific Australia Market – December 2012 Pfizer Market: $14 117m 9% AZ 8% Novartis 6% Others 50% Sanofi 5% Aspen 5% MSD 4% GSK 4% Janssen Source: IMS Health Combined Audit MAT Dec 2012 Roche Cilag Alphapharm 3% 3% (Mylan) 3%  Decline from the $14.2bn in July 2012 ◦ Generic volume growth ◦ Pric

  60. Slide 60: Australia Market – Price and Volume

    Asia Pacific Australia Market – Price and Volume NostraData* Dispensed PBS Value vs Volume YTD Growth 4.00% 2.00% Growth vs last period 0.00% -2.00% -4.00% -6.00% -8.00% Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Volume Growth Value Growth * NostraData uses d

  61. Slide 61: Leading Manufacturers by Scripts Written

    Asia Pacific Australia Market - Leading Manufacturers by Scripts Written 12% ASPEN 20% SANOFI-AVENTIS* PFIZER ASTRAZENECA 9% ALPHAPHARM GLAXOSMITHKLINE* 1% 1% MSD* 1% 8% BOEHRINGER INGELHM MUNDIPHARMA 1% SERVIER 2% ROCHE 2% BAYER PHARMA 2% CSL 2% 8% NOVARTIS* 2% ABBOTT 2% JANSSEN CILAG 2% 7% BRISTOL

  62. Slide 62: Australia's Largest Generic Company by Value

    Asia Pacific Australia’s Largest Generic Company by Value – 16% Australia: Top Generic Players Aspen Remainder $220m $289m 16% 21% Bayer Pharma $35m 3% Alphapharm (Mylan) $179m Ascent Pharma 13% $40m 3% Sanofi-Aventis $63m 5% Hospira $75m Apotex 5% $153m 11% Baxter $76m 6% Pfizer Sandoz $101m $139m

  63. Slide 63: Australia's Largest Generic Company by Volume

    Asia Pacific Australia’s Largest Generic Company by Volume In terms of volume, Aspen is the leading generic player with 20% market share 1154 1721 13% 20% 127 140 1% 196 2% ASPEN 2% 220 ALPHAPHARM 3% BAXTER 493 APOTEX 6% SANDOZ SANOFI-AVENTIS ASCENT 1570 18% PFIZER 666 8% PHARMACARE RECKITT BENCKISE

  64. Slide 64: Australia - Sales Performance

    Asia Pacific Australia - Sales Performance DEC-2012 DEC-2011 TOTAL TOTAL Growth Rm Rm Australia/NZ 3 217 2 737 18% Less: Recent acquisitions OTC brands 76 represents 5 months sales GSK Prescription brands 38 represents 1 months sales Australia Base 3 103 2 737 13%  Base business continues to perfor

  65. Slide 65: Australia – Sales Performance

    Asia Pacific Australia – Sales Performance  Price cuts have been steeper than anticipated ◦ Initial value erosion higher than budgeted ◦ Iterative price reduction will have impact ◦ New base price is being discounted  Challenging market and Aspen continues to out-perform ◦ Great team, great portfo

  66. Slide 66: Australia - Sigma Acquisition Update

    Asia Pacific Australia - Sigma Acquisition Update  Factory closures tracking to plan  In-house Distribution centres closed ◦ All distribution now channelled through a single outsourced third party  Ability to now divest redundant properties at Nobel Park and Croydon  Sales and marketing teams fu

  67. Slide 67: Australia - Operating Performance

    Asia Pacific Australia - Operating Performance  Operating profit margins increased to 28% ◦ Benefits of promised synergies ◦ Improved procurement and COGS ◦ Margin increase in a declining price environment ◦ Synergies greater than price erosion  On going benefits still to harness ◦ Process of movi

  68. Slide 68: Australia - Prospects

    Asia Pacific Australia - Prospects  Extrapolated the OTC and prescription brands ◦ Yields annualised sales of R641m  Have a competent team ◦ Define the Aspen culture ◦ Can be relied upon to deliver the Aspen's broader objectives for Asia  Aspen is really well positioned to take advantage ◦ Of bot

  69. Slide 69: Asia Performance

    Asia Pacific Asia Performance DEC-2012 DEC-2011 TOTAL TOTAL Growth Rm Rm - Asia base 190 156 22% - OTC brands acquired 65 - Total Asia 255 156 64% Revenue of R255m for 6 months ended Dec 2012 Philippines 15% Japan 20% 3% Hong Kong 4% Malaysia Taiwan Thailand 9% Indonesia 24% Rest of Asia 11% 14% Asp

  70. Slide 70: Philippines

    Asia Pacific Philippines  Sales growth of 148% ◦ 84% excluding OTC brands  Sales and promotion deals executed and more in discussion ◦ Merck  Developing strong organic pipeline  Current headcount 106  Already ranked 34th per IMS 70

  71. Slide 71: Malaysia

    Asia Pacific Malaysia  All key staff appointed  All business licences obtained  Trading to begin as Aspen on 1 May 2013  Pipeline being added  34% growth largely driven by OTC products 71

  72. Slide 72: Taiwan

    Asia Pacific Taiwan  Business license obtained  Staff recruitment ongoing  Trading hoped to commence 1 July 2013  Pipeline products being developed  Sales growth of 8% even after mandatory price decreases 72

  73. Slide 73: Indonesia/Japan/Thailand Under Assessment

    Asia Pacific Indonesia/Japan/Thailand Under Assessment  Currently ◦ Reviewing opportunities ◦ Ambition of opening subsidiaries  Challenging markets ◦ Indonesia has local manufacturing requirements ◦ Japan − World’s second largest market − High barriers to entry Indonesia Japan Thailand 73

  74. Slide 74: Asian Prospects

    Asia Pacific Asian Prospects  Key focus area for Aspen ◦ Recruiting resource to drive the business ◦ Reviewing both organic and inorganic opportunities − Tangible opportunities to create further regional mass ◦ Further licensing opportunities also being explored  Increased critical mass important

  75. Slide 75: Sub Saharan Africa Regional Growth Rates

    Sub Saharan Africa Regional Growth Rates Relative Regional Revenue Sales R990m (2011: R835m) Growth Rates Anglophone East Africa West 14% 33% West Africa 37% Africa Southern 21% Africa East 27% Africa Southern Africa 10% French West Africa 20% SSA sales growth of 19% 75

  76. Slide 76: Sub Saharan Africa Highlights

    Sub Saharan Africa Highlights  Sales growth despite political instability in key markets ◦ Kenya and Nigeria  Strong organic growth  Strategic decision made to increase our footprint ◦ More than 650 sales representatives  Private market focus at Shelys ◦ Double digit growth maintained  29 Aspen

  77. Slide 77: Sub Saharan Africa Highlights

    Sub Saharan Africa Highlights  West Africa ◦ Strong performance in Nigeria despite unrest ◦ Additional sales representation − Especially in French speaking countries  Southern Africa and East Africa ◦ Additional sales representatives ◦ Improved revenue in Shelys Africa ◦ Political instability in K

  78. Slide 78: Sub Saharan Africa Outlook for Remaining 6 Months

    Sub Saharan Africa Outlook for the Remaining 6 Months  March elections in Kenya will impact performance  Benefits of additional representation to be realised ◦ Will help sustain current sales growth  Focus on reducing operating expenses ◦ Will not impact representation ◦ Will impact future margin

  79. Slide 79: International: Latam A Strategic Focus

    International: Latam A Strategic Focus  Sales Growth 39% vs previous half year DEC-2012 DEC-2011 TOTAL TOTAL Growth Rm Rm Brazil 386 320 21% Spanish Latam 371 224 66% 757 544 39%  Last year we had a sell in during H1 ◦ Annual sales were R1 026m ◦ If H1 is repeated growth for the year would be clos

  80. Slide 80: Latam Market Segmentation

    International: Latam Market Segmentation  Divided into 6 focus areas ◦ Aspen Brazil Venezuela CEO ◦ Aspen Mexico ◦ Aspen Venezuela ◦ Aspen Andean − Columbia COO Spanish − Ecuador Speaking Latam & Mexico Andean/Caricam − Peru Commercial Manager − Bolivia ◦ Aspen Argentina − Argentina − Chile Brazil

  81. Slide 81: Effectiveness of Commercial Teams in Brazilian Market

    International: Latam Effectiveness of the Introduction of Commercial Teams into Brazilian Market Pharmacy Panel Roles Measurement  Daily control of transfer orders  Brazilian market is dominated  Increase demand through volume. by focus on detail strategies shelf pressure i.e. doctors exclusively

  82. Slide 82: Creating Brands in Brazil

    International: Latam Creating Brands in Brazil 600 000 Insunorm Quarterly Unit sales 516 629 500 000 400 000 Quarter Units 300 000 265 224 200 000 100 000 87 691 61 668 69 298 45 554 51 123 Units 37 181 14 216 - 6 317 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2010 2010 2011 2011 2012 2012 2012 2012 2013 2013 As

  83. Slide 83: Effectiveness of the Sales Force in Brazil

    International: Latam Demonstration of Effectiveness of the Sales Force in Brazil Calman Sales Units 500 000 450 000 449 302 400 000 373 656 350 000 300 000 315 177 310 858 314 213 290 065 279 752 273 087 269 818 250 000 251 422 Units 200 000 150 000 100 000 50 000 - Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 201

  84. Slide 84: OTC – Marketing Campaign in Brazil

    International: Latam OTC – Marketing Campaign makes the difference in Brazil TV Merchandising Magazines Ads Magazines Website and Social Networks POS Material – Shelf space Slimming is a crowded sector 84

  85. Slide 85: Leadership - Alcachofra Brazil

    International: Latam Leadership - Alcachofra Brazil 100000 DDD Sales Units by Quarter 90000 87934 84932 86228 83870 83240 80000 79577 79092 77899 77446 77655 75666 71669 73046 70000 69098 70282 70721 71087 67387 68858 67763 69004 63384 60000 59685 59902 57193 56840 58408 56476 53543 50000 46975 4000

  86. Slide 86: Mexico Private Market

    International: Latam Mexico Private Market Zyloprim - IMS MAT Mexico 450 000 440 000 430 000 420 000 410 000 400 000 Distributors Demand additional discount IMS MAT 390 000 380 000 370 000 360 000 350 000 Aspen Transfer of Distribution 86

  87. Slide 87: Venezuela New Product Launches

    International: Latam Venezuela New Product Launches Venezuela Cumulative New Product Sales January 2012 to December 2012 25 000 000 20 000 000 15 000 000 10 000 000 5 000 000 - Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Cumulative New Product Sales New Produc

  88. Slide 88: Latam Prospects

    International: Latam Prospects  H2 sales to continue current H1 momentum  Replicate successful Brazil pharmacy/commercial strategy ◦ Mexico and Venezuela  Looking for acquisition/partnering or set up opportunities ◦ Caricam, Andean and Argentina  Leverage brand equity of acquired brands ◦ Credib

  89. Slide 89: Group Summary and Prospects

    Group Summary and Prospects Operational Performance  Impressive Financial Performance ◦ Revenue and profits ◦ Margins maintaining ◦ Acquisitions have been bedded down  Performance in all regions encouraging ◦ Strong H1 to continue into H2 Strong Growth both Organically and Acquisitively Corporate

  90. Slide 90: Q&A

    Q&A

Aspen Pharmacare Holdings — H1 2013 Earnings Presentation on 6ix